Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
efficacy endpoints, with expanded results to be presented in a late-breaking oral session at the 2026 MDA Clinical and Scientific Conference alongside additional Yale-led research and four related posters. This successful interim readout marks a significant step for BBP-418 as a potential therapy for a rare genetic muscle disorder, while also underscoring BridgeBio's broader effort to build clinical, economic, and real-world evidence around LGMD2I/R9. Now, we'll examine how this positive Phase 3 interim outcome for BBP-418 could influence BridgeBio's late-stage genetic pipeline investment narrative. This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality BridgeBio Pharma Investment Narrative Recap To own BridgeBio, you need to believe its late stage genetic medicines can broaden the business beyond Attruby, easing heavy reliance on a single drug while the company is still loss making. The positive interim FORTIFY Phase
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]Yahoo! Finance
- BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9GlobeNewswire
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 3/16/26 - Form 4
- 3/13/26 - Form 144
- 3/12/26 - Form 4
- BBIO's page on the SEC website